vs
ARTIVION, INC.（AORT）とRapid7, Inc.（RPD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Rapid7, Inc.の直近四半期売上が大きい（$217.4M vs $116.0M、ARTIVION, INC.の約1.9倍）。ARTIVION, INC.の純利益率が高く（2.1% vs 1.4%、差は0.7%）。ARTIVION, INC.の前年同期比売上増加率が高い（19.2% vs 0.5%）。Rapid7, Inc.の直近四半期フリーキャッシュフローが多い（$36.4M vs $-7.9M）。過去8四半期でARTIVION, INC.の売上複合成長率が高い（9.1% vs 3.0%）
Artivion, Inc.は心血管移植向けの極低温保存した人体組織の流通、及び医療機器の開発を行う医療企業です。同社の製品には、余分な細胞物質と抗原を除去する処理を施した人間の心臓弁、手術用接着剤BioGlueなどがあり、臨床現場のニーズに応えています。
Rapid7社は世界的に有名なサイバーセキュリティ企業で、脆弱性管理、脅威検知・対応、クラウドセキュリティ、セキュリティ分析などの総合的なソリューションを提供しています。テクノロジー、医療、金融、製造業などの各業種の企業や公共部門を顧客とし、サイバー脅威への効率的な対応を支援します。
AORT vs RPD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $116.0M | $217.4M |
| 純利益 | $2.4M | $3.1M |
| 粗利率 | 63.1% | 68.9% |
| 営業利益率 | 9.2% | 1.0% |
| 純利益率 | 2.1% | 1.4% |
| 売上前年比 | 19.2% | 0.5% |
| 純利益前年比 | 114.7% | 44.1% |
| EPS（希薄化後） | $0.06 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $116.0M | $217.4M | ||
| Q3 25 | $113.4M | $218.0M | ||
| Q2 25 | $113.0M | $214.2M | ||
| Q1 25 | $99.0M | $210.3M | ||
| Q4 24 | $97.3M | $216.3M | ||
| Q3 24 | $95.8M | $214.7M | ||
| Q2 24 | $98.0M | $208.0M | ||
| Q1 24 | $97.4M | $205.1M |
| Q4 25 | $2.4M | $3.1M | ||
| Q3 25 | $6.5M | $9.8M | ||
| Q2 25 | $1.3M | $8.3M | ||
| Q1 25 | $-505.0K | $2.1M | ||
| Q4 24 | $-16.5M | $2.2M | ||
| Q3 24 | $-2.3M | $15.4M | ||
| Q2 24 | $-2.1M | $6.5M | ||
| Q1 24 | $7.5M | $1.4M |
| Q4 25 | 63.1% | 68.9% | ||
| Q3 25 | 65.6% | 70.2% | ||
| Q2 25 | 64.7% | 70.6% | ||
| Q1 25 | 64.2% | 71.7% | ||
| Q4 24 | 63.2% | 69.5% | ||
| Q3 24 | 63.7% | 70.6% | ||
| Q2 24 | 64.6% | 70.7% | ||
| Q1 24 | 64.6% | 70.3% |
| Q4 25 | 9.2% | 1.0% | ||
| Q3 25 | 11.1% | 2.7% | ||
| Q2 25 | 7.4% | 1.6% | ||
| Q1 25 | 2.2% | -0.0% | ||
| Q4 24 | 2.7% | 3.4% | ||
| Q3 24 | 4.6% | 6.0% | ||
| Q2 24 | 6.6% | 2.5% | ||
| Q1 24 | 26.0% | 4.7% |
| Q4 25 | 2.1% | 1.4% | ||
| Q3 25 | 5.7% | 4.5% | ||
| Q2 25 | 1.2% | 3.9% | ||
| Q1 25 | -0.5% | 1.0% | ||
| Q4 24 | -16.9% | 1.0% | ||
| Q3 24 | -2.4% | 7.2% | ||
| Q2 24 | -2.2% | 3.1% | ||
| Q1 24 | 7.7% | 0.7% |
| Q4 25 | $0.06 | $0.05 | ||
| Q3 25 | $0.13 | $0.15 | ||
| Q2 25 | $0.03 | $0.13 | ||
| Q1 25 | $-0.01 | $0.03 | ||
| Q4 24 | $-0.40 | $0.08 | ||
| Q3 24 | $-0.05 | $0.21 | ||
| Q2 24 | $-0.05 | $0.09 | ||
| Q1 24 | $0.18 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $64.9M | $474.7M |
| 総負債低いほど良い | $215.1M | — |
| 株主資本純資産 | $448.2M | $154.7M |
| 総資産 | $884.8M | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $64.9M | $474.7M | ||
| Q3 25 | $73.4M | $407.1M | ||
| Q2 25 | $53.5M | $511.7M | ||
| Q1 25 | $37.7M | $493.5M | ||
| Q4 24 | $53.5M | $521.7M | ||
| Q3 24 | $56.2M | $443.7M | ||
| Q2 24 | $55.0M | $442.6M | ||
| Q1 24 | $51.1M | $411.7M |
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
| Q4 25 | $448.2M | $154.7M | ||
| Q3 25 | $438.7M | $127.2M | ||
| Q2 25 | $419.9M | $90.4M | ||
| Q1 25 | $294.3M | $52.7M | ||
| Q4 24 | $276.2M | $17.7M | ||
| Q3 24 | $304.7M | $-5.1M | ||
| Q2 24 | $295.1M | $-52.6M | ||
| Q1 24 | $295.0M | $-86.4M |
| Q4 25 | $884.8M | $1.7B | ||
| Q3 25 | $857.7M | $1.7B | ||
| Q2 25 | $838.4M | $1.6B | ||
| Q1 25 | $791.2M | $1.6B | ||
| Q4 24 | $789.1M | $1.7B | ||
| Q3 24 | $803.1M | $1.6B | ||
| Q2 24 | $789.5M | $1.5B | ||
| Q1 24 | $784.0M | $1.5B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.6M | $37.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $-7.9M | $36.4M |
| FCFマージンFCF / 売上 | -6.9% | 16.8% |
| 設備投資強度設備投資 / 売上 | 23.7% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 8.06× | 12.01× |
| 直近12ヶ月FCF直近4四半期 | $839.0K | $146.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.6M | $37.6M | ||
| Q3 25 | $22.3M | $39.0M | ||
| Q2 25 | $15.0M | $47.5M | ||
| Q1 25 | $-17.0M | $29.8M | ||
| Q4 24 | $10.1M | $63.8M | ||
| Q3 24 | $11.5M | $44.0M | ||
| Q2 24 | $6.1M | $32.9M | ||
| Q1 24 | $-5.5M | $31.1M |
| Q4 25 | $-7.9M | $36.4M | ||
| Q3 25 | $17.7M | $34.8M | ||
| Q2 25 | $11.7M | $46.6M | ||
| Q1 25 | $-20.6M | $28.4M | ||
| Q4 24 | $8.7M | $62.6M | ||
| Q3 24 | $7.8M | $42.6M | ||
| Q2 24 | $3.6M | $32.6M | ||
| Q1 24 | $-9.1M | $30.4M |
| Q4 25 | -6.9% | 16.8% | ||
| Q3 25 | 15.6% | 16.0% | ||
| Q2 25 | 10.4% | 21.8% | ||
| Q1 25 | -20.8% | 13.5% | ||
| Q4 24 | 9.0% | 28.9% | ||
| Q3 24 | 8.2% | 19.9% | ||
| Q2 24 | 3.7% | 15.7% | ||
| Q1 24 | -9.3% | 14.8% |
| Q4 25 | 23.7% | 0.5% | ||
| Q3 25 | 4.1% | 1.9% | ||
| Q2 25 | 2.9% | 0.4% | ||
| Q1 25 | 3.7% | 0.6% | ||
| Q4 24 | 1.5% | 0.5% | ||
| Q3 24 | 3.8% | 0.6% | ||
| Q2 24 | 2.6% | 0.1% | ||
| Q1 24 | 3.7% | 0.3% |
| Q4 25 | 8.06× | 12.01× | ||
| Q3 25 | 3.42× | 3.97× | ||
| Q2 25 | 11.16× | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | -0.73× | 22.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
